

Accepted Manuscript

A Pilot Trial of Lirilumab with or without Azacitidine for patients with Myelodysplastic Syndrome

Fevzi Firat Yalniz, Naval Daver, Katayoun Rezvani, Steven Kornblau, Maro Ohanian, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Jan Burger, Yvonne Gasior, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

PII: S2152-2650(18)30443-9

DOI: [10.1016/j.clml.2018.06.011](https://doi.org/10.1016/j.clml.2018.06.011)

Reference: CLML 1138

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 7 May 2018

Revised Date: 4 June 2018

Accepted Date: 11 June 2018

Please cite this article as: Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G, A Pilot Trial of Lirilumab with or without Azacitidine for patients with Myelodysplastic Syndrome, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2018.06.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



A Pilot Trial of Lirilumab with or without Azacitidine for patients with Myelodysplastic Syndrome

Fevzi Firat Yalniz¹, Naval Daver¹, Katayoun Rezvani², Steven Kornblau, Maro Ohanian¹, Gautam Borthakur¹, Courtney D. DiNardo¹, Marina Konopleva¹, Jan Burger¹, Yvonne Gasior¹, Sherry Pierce¹, Hagop Kantarjian¹, Guillermo Garcia-Manero¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas; ²Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas

Corresponding Author

Guillermo Garcia-Manero MD
Department of Leukemia
MD Anderson Cancer Center Box 428
1515 Holcombe Blvd Houston, TX 77030
E-mail: ggarciam@mdanderson.org

Keywords

Myelodysplastic syndrome; anti-KIR therapy; natural killer cells, azacitidine, lirilumab

Authorship Contributions

FFY and GGM wrote the manuscript. All authors contributed substantially to the conception, acquisition, analysis, and interpretation of the data for the work and approved the final approval of the version to be published.

Download English Version:

<https://daneshyari.com/en/article/10211916>

Download Persian Version:

<https://daneshyari.com/article/10211916>

[Daneshyari.com](https://daneshyari.com)